Cidara Therapeutics Highlights New Data from Multiple Rezafungin Studies Presented at ECCMID 2019

SAN DIEGO–(BUSINESS WIRE)–Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, highlighted new data from multiple studies of rezafungin, the company’s lead investigational compound, this week during the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands. Rezafungin is the only once-weekly product candidate in development for the treatment and prevention of life-thre

Click to view original post

Advertise With Us